SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 25.82 |
Enterprise Value ($M) | 16.33 |
Book Value ($M) | -11.38 |
Book Value / Share | -0.71 |
Price / Book | -2.27 |
NCAV ($M) | -12.69 |
NCAV / Share | -0.79 |
Price / NCAV | -2.03 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | -1.10 |
Return on Equity (ROE) | -2.14 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.95 |
Current Ratio | 1.09 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 12.25 |
Assets | 13.55 |
Liabilities | 24.94 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 4.85 |
Operating Income | -33.49 |
Net Income | -27.54 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -28.42 |
Cash from Investing | -3.43 |
Cash from Financing | 9.90 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 4.99 | -31.74 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
83,759 | 349,414 | 23.97 | |
47,800 | 112,443 | 42.51 | |
45,643 | 187,139 | 24.39 | |
17,614 | 104,605 | 16.84 | |
(click for more detail) |
Similar Companies | |
---|---|
OGEN – Oragenics, Inc. | PHGE – BiomX Inc. |
PLX – Protalix BioTherapeutics, Inc. | TOVX – Theriva Biologics, Inc. |
VCXB – 10X Capital Venture Acquisition Corp. III |